

Apixaban (Eliquis) Drug Level, Medical 303

Table of Content

- [Purpose](#)
- [Description & Definitions](#)
- [Criteria](#)
- [Coding](#)
- [Document History](#)
- [References](#)
- [Special Notes](#)
- [Keywords](#)

<u>Effective Date</u>	4/2019
<u>Next Review Date</u>	6/2025
<u>Coverage Policy</u>	Medical 303
<u>Version</u>	4

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual’s benefit plan for details*.

Purpose:

This policy addresses the medical necessity of Apixaban (Eliquis) Drug Level.

Description & Definitions:

Apixaban Drug Level testing the level of a direct oral anticoagulant (DOAC) medication in the blood stream.

Criteria:

Apixaban (Eliquis) Drug Level is considered not medically necessary for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
80299	Quantitation of therapeutic drug, not elsewhere specified.

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

Reviewed Dates:

- 2024: June – no changes references updated

- 2023: June

- 2022: June
- 2021: August
- 2020: August

Effective Date:

- April 2019

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

Federal Register. Daily Journal of the United States Government. Retrieved 5.30.2024.
<https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=apixaban>

U.S. Food and Drug Administration. Understanding the contribution of laboratory data linked to administrative claims: a case study looking at renal function and oral anticoagulant performance in patients with atrial fibrillation. 11.17.2023. Retrieved 5.30.2024. <https://www.fda.gov/science-research/advancing-regulatory-science/understanding-contribution-laboratory-data-linked-administrative-claims-case-study-looking-renal>

Hayes. A symplr company. Retrieved 5.30.2024.
[https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Apixaban%2520\(Eliquis\)%2520Drug%2520Level%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%25220,%2522size%2522:50%2527D,%2522type%2522:%2522all%2522,%2522sources%2522:%2522%2522*%2522%2527D,%2522sorts%2522:%2522%2527B%2527B%2522field%2522:%2522_score%2522,%2522direction%2522:%2522desc%2522%2527D%2527D,%2522filters%2522:%2522%2527B%2527B%2527D](https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Apixaban%2520(Eliquis)%2520Drug%2520Level%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%25220,%2522size%2522:50%2527D,%2522type%2522:%2522all%2522,%2522sources%2522:%2522%2522*%2522%2527D,%2522sorts%2522:%2522%2527B%2527B%2522field%2522:%2522_score%2522,%2522direction%2522:%2522desc%2522%2527D%2527D,%2522filters%2522:%2522%2527B%2527B%2527D)

MCG Informed Care Strategies. Retrieved 5.30.2024. <https://careweb.careguidelines.com/ed27/index.html>

Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 5.30.2024.
<https://www.cms.gov/search/cms?keys=80299>

Commonwealth of Virginia. Department of Medical Assistance Services. Retrieved 5.30.2024
<https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=80299&gsc.sort=>

Commonwealth of Virginia. Department of Medical Assistance Services. DMAS Fee Schedule. Retrieved 5.30.2024 <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

National Comprehensive Cancer Network. Submission Request History. Apixaban Submitted by Bristol-Myers Squibb Company on 04/06/2020. Retrieved 5.30.2024. <https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history>

Carelon clinical guidelines and pathways. Retrieved 5.30.2024.
<https://guidelines.carelonmedicalbenefitsmanagement.com/no-search-results-found/>

Avalon. Retrieved 5.30.2024. <https://www.avalonhcs.com/policies-sentarahealth/>

American College of Cardiology. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Jan 2024. Retrieved 5.30.2024.
https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017?_ga=2.105885259.976840480.1717093444-469703599.1711482484

Towers, W., Nguyen, S. N., Ruegger, M. C., Salazar, E., & Donahue, K. R. (2022). Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury. *The Annals of pharmacotherapy*, 56(6), 656–663. Retrieved 5.30.2024. <https://doi.org/10.1177/10600280211046087>

Special Notes: *

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Keywords:

SHP Apixaban Drug Level, SHP Medical 303, blood test, Eliquis